For decades, a diabetes diagnosis meant facing instant declinations or exorbitant premium surcharges when shopping for individual life coverage. Today, advances in clinical management, continuous glucose monitoring (CGM), and modern mortality data have transformed how carriers evaluate metabolic risk.
Securing the best term life insurance for diabetics is entirely achievable. Whether you are managing Type 2 diabetes with diet and oral medications or living with insulin-dependent Type 1 diabetes, knowing how carriers interpret your HbA1c levels, age of onset, and microvascular health is key to avoiding unnecessary table ratings.
How Underwriters Evaluate Diabetic Applicants
Life insurance medical underwriters look past the diagnostic label to evaluate long-term glycemic control and cardiovascular risk:
- The HbA1c Threshold: The primary benchmark in underwriting is your average blood sugar over the preceding 90 days. An A1C below 7.0% generally qualifies for standard or even preferred non-tobacco tiers at select carriers. An A1C between 7.0% and 8.0% usually triggers minor table ratings, while levels above 9.0%–9.5% often lead to declinations or require guaranteed-issue alternatives.
- Age of Onset: Developing Type 2 diabetes after age 45 carries substantially less underwriting penalty than childhood or adolescent onset, because the cumulative timeline for chronic vascular damage is significantly compressed.
- Absence of End-Organ Complications: Underwriters cross-reference your records for diabetic nephropathy (protein in urine), peripheral neuropathy (nerve tingling/numbness), and retinopathy (retinal damage). A clean complication history keeps premiums accessible.
- Treatment Regimen: Diet-controlled Type 2 ranks most favorably, followed by single-agent oral regimens (such as Metformin) and modern GLP-1 receptor agonists. Insulin therapy automatically places applicants into higher risk bands.
Top Life Insurance Carriers for Diabetes
| Carrier | Best For | Typical Underwriting Advantage |
| Banner Life (Legal & General) | Best overall term rates for Type 2 | Competitive baseline rates; flexible underwriting for controlled A1C under 7.5%. |
| John Hancock | Health management & incentives | Offers the Aspire Program, delivering premium discounts for tracking nutrition and exercise via Vitality. |
| Prudential | Higher A1C & complex medical files | Willing to approve Type 2 applicants with A1C levels up to 8.0%–8.5% and mild comorbid hypertension. |
| Corebridge Financial (AIG) | Well-managed Type 1 cases | More favorable baseline classifications for long-standing insulin-dependent applicants. |
| Mutual of Omaha | Simplified / No-exam term | Strong underwriting credits for older adults seeking fast coverage without clinic blood draws. |
Understanding Table Ratings and Policy Pricing
If your health profile does not qualify for Standard pricing, underwriters assign a Table Rating. Table ratings apply a percentage surcharge on top of the standard premium base:
- Standard: Base premium (0% surcharge).
- Table 2 (Table B): Standard rate + 50% surcharge (common for well-controlled Type 2 with mild cholesterol elevation).
- Table 4 (Table D): Standard rate + 100% surcharge (frequent benchmark for well-managed Type 1 applicants or Type 2 with A1C near 8.0%).
- Table 6 (Table F) to Table 8 (Table H): Standard rate + 150% to 200% surcharge (reserved for fluctuating control, insulin dependence, or early-stage microalbuminuria).
Steps to Maximize Approval Before Applying
- Wait for Consistent Lab Work: If you recently adjusted medication dosages, wait 90 days for your updated A1C to stabilize before completing the paramedical blood draw.
- Compile Detailed Treatment Records: Secure copies of routine endocrinologist visit notes, annual dilated eye exam results, and microalbumin urine tests to demonstrate proactive disease oversight.
- Work with an Independent Impaired-Risk Broker: Avoid captive agents bound to a single underwriter. Independent brokers can shop informal applications to multiple medical directors simultaneously without triggering an official rejection mark in the Medical Information Bureau (MIB) database.